

Astellas APAC GU Masterclass

Friday, July 11, 2025, 18:30–20:15 KST

Saturday, July 12, 2025, 08:30–13:00 KST

Conrad Seoul, Seoul, South Korea

EV as first-line therapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer. Combination therapy with pembrolizumab.

EV as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor and have received a platinum-containing chemotherapy.

EV, enfortumab vedotin.
PADCEV® (enfortumab vedotin). Prescribing Information.
July 2025 | MAT-KR-PAD-2025-00059

Adverse events should be reported.

For Korea, healthcare professionals are asked to report any suspected adverse reactions to Astellas Pharma Korea, Inc.

(Telephone: +82 10 5254 3389; Email: safety-kr@kr.astellas.com)

Prescribing Information is available at the end of this presentation. This promotional meeting is fully sponsored and supported by Astellas, including speaker-related honoraria and production of materials. It is intended for healthcare professionals only.

 **PADCEV**
enfortumab vedotin
Injection for IV infusion 20 mg & 30 mg vials **astellas**

Disclaimers

The information, views and opinions presented herein are those of the presenter, and the presenter is solely responsible for the materials being introduced in this presentation. Although patients' cases mentioned herein are actual cases, treatment may differ from local approval product information.

Such information, views and opinions of the presenter do not necessarily reflect the information, views and opinions of Astellas Pharma Ltd. Astellas Pharma Ltd. does not recommend the use of any product in any different manner than as described in the local approval information, and complies with all applicable laws, regulations, and company policies.

Introduction from Astellas

Astellas Korea

Welcome and introduction

Professor Sang Joon Shin

Yonsei Cancer Center, Yonsei University College of Medicine,
Seoul, South Korea

Speaker disclosures

Holds stock in:

- AIGEN Science Inc.
- DAAN Biotherapeutics Inc.
- GI BIOME
- Oncosoft

Employment:

- CEO of Xactus Onco Inc.

Meeting objectives



To discuss the evolving treatment landscape of LA/mUC, highlighting recent data updates on new molecules and clinical guideline changes



To discuss strategies for achieving optimal treatment outcome with EV monotherapy / EV+P by presenting the recent data updates of EV including RWE, EV-302 Pan-Asia data, PK data, and other subanalyses



To share clinical outcomes and the role of EV in 2L and EV+P in 1L from real practices to demonstrate optimal treatment strategy of EV and effective management of AEs



To establish a specialized platform featuring global experts of XTANDI™ (enzalutamide) and PADCEV™ (enfortumab vedotin) to support their integration into clinical practice

Agenda [1/4]

Friday, July 11, 2025

Time (KST)	Session	Speakers
18:30–18:45 (15 min)	Astellas introduction (PCa and BCa)	Astellas Korea
	Welcome and introduction from Chair	Prof. Sang Joon Shin (KR)
18:45–19:15 (30 min)	Setting the scene: Understanding the LA/mUC treatment landscape	Dr Alejo Rodríguez-Vida (EU) Prof. Daniel Petrylak (US)
19:15–20:15 (60 min)	Revision and reflection: Assessing the impact of recent changes in the LA/mUC treatment landscape	Dr Alejo Rodríguez-Vida (EU) Prof. Daniel Petrylak (US) Dr Kaiwei Yang (China)

Agenda [2/4]

Saturday, July 12, 2025 – Breakout room 1

Time (KST)	Session	Speakers
-	<i>Breakfast and move to breakout rooms</i>	-
08:30–09:15 (45 min)	On the horizon: Recent data for 2L treatment of patients with unresectable LA/mUC	Dr Niara Oliveira (Moderator) Dr Alejo Rodriguez-Vida (EU) Dr Ashok Kumar Vaid (India) Dr Mark Igorevich (RU)
09:15–10:00 (45 min)	Best practice sharing: Practical approaches to patient care in 2L treatment (part 1)	Dr Alejo Rodriguez-Vida (Moderator) Dr Phichai Chansriwong (Thailand) Prof. Yüksel Ürün (Turkey)
10:00–10:20 (20 min)	<i>Break</i>	-
10:20–11:00 (40 min)	Best practice sharing: Practical approaches to patient care in 2L treatment (part 2)	Dr Alejo Rodriguez-Vida (Moderator) Dr Phichai Chansriwong (Thailand) Prof. Yüksel Ürün (Turkey)

For attendees from: Russia, Malaysia, and Hong Kong

Agenda [3/4]

Saturday, July 12, 2025 – Breakout room 2

Time (KST)	Session	Speakers
-	<i>Breakfast and move to breakout rooms</i>	-
08:30–09:15 (45 min)	On the horizon: Recent data for 1L standard of care treatment of unresectable LA/mUC	Prof. Daniel Petrylak (US) Dr Ye YAN (CN) Prof. Eun Hee Jung (KR)
09:15–10:00 (45 min)	Best practice sharing: Practical approaches to patient care in 1L treatment (part 1)	Prof. Daniel Petrylak (US) Prof. Jungmin Jo (KR) Dr Jiun-I Lai (TW)
10:00–10:20 (20 min)	<i>Break</i>	-
10:20–11:00 (40 min)	Best practice sharing: Practical approaches to patient care in 1L treatment (part 2)	Prof. Daniel Petrylak (US) Prof. Jungmin Jo (KR) Dr Jiun-I Lai (TW)

For attendees from: South Korea, China, Taiwan, Australia, Singapore, Turkey, and Thailand

Agenda [4/4]

Saturday, July 12, 2025

Time (KST)	Session	Speakers
11:00–11:20 (20 min)	<i>Return to plenary room</i>	-
11:20–12:30 (70 min)	Principles of AE management with standard of care	Dr Niara Oliveira (Moderator) Prof. Daniel Petrylak (US) Dr Johan Chan (SG) Dr Kristen Yeo (SG)
12:30–12:50 (20 min)	Principles of AE management with standard of care: Ask the experts	All Faculty
12:50–13:00 (10 min)	Thank you and close for LA/mUC	Astellas
13:00–14:00 (60 min)	<i>Lunch</i>	-

Faculty



Professor Sang
Joon Shin
(co-Chair),
South Korea



Dr Alejo
Rodriguez-Vida
(co-Chair), Spain



Professor
Daniel Petrylak,
(co-Chair), US



Dr
Niara Oliveria,
(co-Chair),
Australia



Dr Kaiwei Yang,
China



Dr Ashok
Kumar Vaid,
India



Dr Mark
Igorevich Gluzman,
Russia



Dr Phichai
Chansriwong,
Thailand



Professor
Yüksel Ürün,
Turkey



Dr Ye Yan,
China



Professor
Eun Hee Jung,
South Korea



Professor
Jungmin Jo,
South Korea



Dr Jiun-I Lai,
Taiwan




Dr Johan Chan,
Singapore



Dr Kristen Yeo,
Singapore


Housekeeping



Please put your electronic devices on silent mode



Submit your questions throughout the meeting via the Onomi app



Please note this meeting is being recorded and livestreamed online

How to submit questions/use polls

Please scan the QR code on your mobile device to submit questions and respond to polls

- Once downloaded, please open the Onomi app
- Tap on 'Get Started'
- Next, tap on 'Email me a magic link' and check your inbox. You will receive a 6-digit code, which you will need to input into your device
- You will then need to agree to the GDPR and Terms and Conditions before the app can begin to download content to your device



We want to hear your opinions during polling questions and the Q&A session!

Make the most out of today's sessions



Please do get involved in the
Q&A sessions and engage
with our expert faculty



Submit questions via
the Onomi app or live
using the roaming microphone

Question for the audience

How would you describe your experience in treating patients with LA/mUC?

- A** Mainly 1L
- B** Mainly 2L
- C** Both 1L and 2L
- D** No experience

Where would you most like to visit on your next trip to Seoul?

A



Gyeongbokgung Palace

B



N Seoul Tower (Namsan)

C



Bukchon Hanok Village

D



Gwangjang Market

Urothelial carcinoma can develop anywhere in the urinary tract but most commonly originates in the bladder¹

UC origin

Frequency

Upper tract (renal pelvis/ureter)



5–10% of UC cases in Western countries;^{2,3} may be **higher in other regions** e.g. UTUC accounts for ~30% of all UC in Eastern Asia;⁴ due to risk factors such as the use of AA-containing herbal medicines⁵

60%
of UTUCs
are invasive³

Bladder




90–95% of UC cases in Western countries^{2,5}
70–80% in Taiwan⁵

15–25%
of bladder cancers
are invasive³

AA, aristolochic acid; UC, urothelial carcinoma; UTUC, upper tract urothelial carcinoma.

1. Alderson M et al. *Bladder Cancer* 2020;6:107–122; 2. Roupret M et al. *Eur Urol* 2018;73:111–122; 3. Powles T et al. *Ann Oncol* 2022;33:244–258; 4. Sheu ZL, et al. *Front Oncol* 2022;12:956352; 5. Chen IH et al. *Molecules* 2019;24:3707.


There is variability in the incidence and prevalence of different cancer types across all patient populations*




*2022 Global cancer statistics, male n=10,306,455, female n=9,658,356 total cancers.
Bray F et al. *CA Cancer J Clin* 2024;74:229–263.

The incidence and prevalence of bladder cancer varies between sexes*


Females: Incidence



Males: Incidence (%)




Both sexes: Incidence



*2022 Global cancer statistics, male n=10,306,455, female n=9,658,356 total cancers.
Bray F et al. *CA Cancer J Clin* 2024;74:229–263.

The incidence and prevalence of bladder cancer varies between regions

Region-specific incidence age-standardized rate by sex for bladder cancer in 2022



Bladder cancer affects **more men than women** across the Asia-Pacific regions


Bladder cancer is in the top 15 most prevalent cancers in Korea and is more common in males than females

In 2022, bladder was the 14th highest type of new cancer cases in Korea, with 5261 cases

- 4197 cases were male, with 1064 female cases

There were 1602 deaths from bladder cancer

- 1203 deaths were male, whilst 399 deaths were female




Stage distribution at diagnosis (%)

Localized	22.0	65.0	52.3	38.4	45.7	37.9	12.5	73.2	24.6	72.6
Regional	27.3	19.3	25.6	40.0	25.5	54.4	31.2	11.8	45.4	10.7
Distant	43.5	11.0	9.7	16.0	15.6	1.1	46.4	10.8	20.2	4.2


*Includes gallbladder and other/unspecified parts of the biliary tract.
Park EH, et al. *Cancer Res Treat* 2025;57:312–330.

Bladder cancer survival is worse for patients with regional and distant metastases, compared with localized disease¹

Bladder cancer incidence in Korea, 2002–2022²




5-year relative survival by stage at diagnosis¹



1. National Cancer Institute. SEER 5-year relative survival rates, 2015–2021. Available at: <https://seer.cancer.gov/statistics-network/explorer/application.html>. Accessed: July 2025; 2. National Cancer Registry. Annual report of cancer statistics in Korea 2022. Available at: <https://www.cancer.go.kr/>. Accessed: July 2025.


Clinical management of UBC has expanded over the past decade



*With carcinoma *in situ* unable/unwilling to undergo cystectomy.

BCG, Bacillus Calmette-Guérin; MIBC, muscle-invasive bladder cancer; LA, locally advanced; m, metastatic; mUBC, metastatic urothelial bladder cancer; NMIBC, non-muscle-invasive bladder cancer; UBC, urothelial bladder cancer. Zang J et al. *Front Oncol* 2021;11:696716.

In the past 5 years, multiple treatments have been approved for 1L treatment of advanced UC^{1–15}



Among various clinical trials, only a few PD-1/L1 regimens have achieved success as 1L treatments

1L, first line; Carbo; carboplatin; Cis, cisplatin; dd, dose-dense; EV, enfortumab vedotin; Gem, gemcitabine; MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; Nivo, nivolumab; P, pembrolizumab; UC, urothelial carcinoma.
 1. Cisplatin [package insert]. Durham, NC: Accord Healthcare, Inc; 2. Galluzzi L et al. *Oncogene* 2012;31:1869–1883; 3. Sternberg CN et al. *J Urol* 1985;133:403–407; 4. Stadler WM et al. *J Clin Oncol* 1997;15:3394–3398;
 5. von der Maase H et al. *J Clin Oncol* 2000;18:3068–3077; 6. Sternberg CN et al. *J Clin Oncol* 2001;19:2638–2646; 7. De Santis M et al. *J Clin Oncol* 2012;30:191–199; 8. Suzman DL, et al. *Oncologist* 2018;24:563–569; 9. Merck. Press release September 2017. Available at: <https://www.merck.com/news/european-commission-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer>. Last accessed: March 2025; 10. Roche. Press release. September 2017. Available at: <https://www.roche.com/media/releases/med-cor-2017-09-22c>. Last accessed March 2025; 11. Pfizer. Press release. February 2021. Available at: [pfizer.com/news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line](https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line). Last accessed: March 2025; 12. FDA. Press release. December 2023. Available at: [fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer). Last accessed: March 2025; 13. Bristol Myers Squibb. Press release. March 2024. Available at: [news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx](https://www.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx). Last accessed: March 2025; 14. Bristol Myers Squibb. May 2024. Available at: <https://www.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx>. Last accessed: March 2025; 15. EMA. Summary of opinion. February 2025. Available at: [ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-padcev-ii-13_en.pdf](https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-padcev-ii-13_en.pdf). Last accessed: March 2025.

Please refer to the Korean PI for
PADCEV[®] (enfortumab vedotin) via the
following link or QR Code:

<[PADCEV 20mg](#)>



<[PADCEV 30mg](#)>

